Intellia Therapeutics
30-Second Executive Brief
Executive Assessment
Intellia Therapeutics functions as an established institution within Healthcare & Life Sciences, backed by 63% sourcing coverage, though its relative influence is cooling.
- Maintains 3 mapped relationships across the graph
- 63% sourcing coverage across sourced relationships
- Tracked as established institution within the Healthcare & Life Sciences category
Executive Snapshot
- Strategic Role
- Established Institution
- Sourcing Coverage
- 63%
- Ecosystem Influence
- High
- Strategic Momentum
- Decelerating
View Methodology →
Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.
Coverage
- Mapped Relationships
- 3
- Technology Domains
- 4
Strategic Implications
- Central node connecting multiple strategic ecosystems
- Directly influences technology and capital flows
- Material relevance to downstream dependency mapping
Top Opportunities
Top Risks
Critical Dependencies
Intellia Therapeutics is a CRISPR gene-editing company that reported Phase 3 success in April 2026 for lonvo-z, an in vivo CRISPR therapy that inactivates a liver gene to reduce hereditary angioedema (HAE) swelling attacks -- an 87% reduction in attack rate versus placebo across an 80-patient study, with 62% of treated patients attack-free and therapy-free versus 11% on placebo. Intellia has begun a rolling FDA submission seeking approval of what could become the first in vivo gene-editing therapy to reach market for any disease, targeting a 2027 launch if approved, with a favorable safety profile limited mainly to infusion-related reactions, headaches and fatigue.
Leading Indicators
Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.
Additional Intelligence Signals
Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.
Earnings-call mentions
Mentions Regeneron Pharmaceuticals
“its ability to optimize the impact of its collaborations on its development programs, including, but not limited to, its collaboration with Regeneron Pharmaceuticals, Inc. ("Regeneron") and their co-development program for ATTR amyloidosis”
SEC 8-K exhibit (0001193125-26-215721) · May 11, 2026
Mentions Regeneron Pharmaceuticals
“Collaboration revenue was $7.7 million for the second quarter of 2026, compared to $14.2 million for the second quarter of 2025. The decrease is primarily due to a reduction in revenue from Regeneron.”
SEC 8-K exhibit (0001193125-26-336772) · Aug 6, 2026
Sources
Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.
Evidence
2 sources
- CNBC / STAT News — Intellia's CRISPR gene-editing treatment succeeds in Phase 3 trial for hereditary angioedemanews
- Wall Street Reporter — Intellia stock surges 38% as rolling BLA nears completion under RMAT designationmarket-data
Latest Activity
Insider Filing Activity
Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026
Acquisition & Investment Fit
AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.
Relationship Map
The relationships surrounding Intellia Therapeutics — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.
Connection type
Click any node to make it the new center. Scroll to zoom, drag to pan.
The Story So Far (last 6 months)
Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.
Market Intelligence
UnverifiedCredibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.
Being first to market with an in vivo gene-editing therapy is worth more than lonvo-z's standalone revenue potential
33% confidenceIntellia's lonvo-z is on track to become the first approved in vivo CRISPR gene-editing therapy for any disease, targeting a 2027 launch for hereditary angioedema, a relatively narrow rare-disease indication.
This is InsightNodes' own interpretive read: hereditary angioedema is a small patient population, so lonvo-z's direct commercial opportunity is modest relative to Intellia's current market value -- the larger strategic prize is regulatory and clinical precedent: being first to prove an in vivo CRISPR therapy can be safely dosed, administered, and approved would de-risk the entire category for Intellia's broader liver-disease pipeline and for competitors like CRISPR Therapeutics, making lonvo-z's approval a bellwether event for gene-editing therapeutics generally rather than just a single-product launch.
InsightNodes analysis of Intellia Therapeutics 2026 developments · Aug 14, 2026
Intellia Therapeutics's Timeline
A sourced, dated history of Intellia Therapeutics's key moments — founding to present.
Apr 2026 · Begins rolling FDA submission for first in vivo gene-editing therapy
Based on its Phase 3 data, Intellia began a rolling FDA submission for lonvo-z, positioning it as a candidate to become the first in vivo CRISPR gene-editing therapy approved for any disease, with a planned 2027 launch if approved.
Apr 2026 · Lonvo-z succeeds in Phase 3 trial for hereditary angioedema
Intellia reported that lonvo-z, its in vivo CRISPR-based therapy inactivating a liver gene to reduce the protein driving hereditary angioedema swelling attacks, succeeded in an 80-patient Phase 3 trial, cutting attack rates by 87% versus placebo, with 62% of treated patients attack-free and therapy-free versus 11% in the control arm.
Jul 2026 · Stock surges 38% as RMAT-designated rolling BLA nears completion
Intellia's stock surged 38% over the prior month as investors anticipated a U.S. launch in the first half of 2027; the company expects to complete its rolling Biologics License Application for lonvo-z in the second half of 2026 under the FDA's regenerative medicine advanced therapy (RMAT) designation, which allows portions of the BLA to be submitted on an ongoing basis and provides the FDA an opportunity to accelerate review.